Charting a path toward combination therapy for Alzheimer’s disease
Abstract
It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A combinatorial treatment strategy for Alzheimer disease seems more likely to yield clinical successes than monotherapy, based on treatment paradigms for other chronic diseases.
“Using the example of treatment paradigms for other chronic diseases, such as hypertension, congestive heart failure, epilepsy, HIV and others, a combinatorial treatment strategy for AD seems more likely to yield clinical successes than monotherapy (Gauthier et al., 2019; Morris, 2019; Stephenson et al., 2015).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Stephenson et al., 2015
Cites
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806 · see citing works
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · see citing works
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052 · see citing works
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · see citing works
Self-citationA History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,973 · see citing works
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,291 · see citing works
Self-citationAlzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · see citing works
Donepezil and memantine for moderate-to-severe Alzheimer's disease
Howard, R., McShane, R., Lindesay, J., Ritchie, C., Baldwin, A., Barber, R., Burns, A., Dening, T., Findlay, D., Holmes, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106668 · Cited by 782 · see citing works
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Barker, A., Sigman, C. C., Gj, K., Hylton, N., Berry, D., & Esserman, L. J. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.68 · Cited by 767 · see citing works
Self-citationBiomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H. J., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 630 · see citing works
Self-citationTesting the Right Target and Right Drug at the Right Stage
Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550 · see citing works
Self-citationJack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531 · see citing works
Development of Novel Combination Therapies
Woodcock, J., Griffin, J. P., & Behrman, R. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1101548 · Cited by 248 · see citing works
Evidence for Ordering of Alzheimer Disease Biomarkers
Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 221 · see citing works
Adaptive Clinical Trials: The Promise and the Caution
Berry, D. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2685 · Cited by 214 · see citing works
Self-citationBaselga, J. (2001) · Oncology · doi:10.1159/000055397 · Cited by 180 · see citing works
Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease
Jack, C. R., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Lowe, V., Kantarci, K., Bernstein, M. A., Senjem, M. L., Gunter, J. L., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3405 · Cited by 145 · see citing works
Gauthier, S. G., & Molinuevo, J. L. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.11.005 · Cited by 111 · see citing works
Romero, K., de Mars, M., Frank, D. H., Anthony, M., Neville, J., Kirby, L., Smith, K., & Woosley, R. L. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.165 · Cited by 55 · see citing works
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI
Peters, O., Lorenz, D., Fesche, A., Schmidtke, K., Hüll, M., Perneczky, R., Rüther, E., Möller, H. ‐., Jessen, F., Maier, W., et al. (2012) · The journal of nutrition health & aging · doi:10.1007/s12603-012-0062-8 · Cited by 55 · see citing works
Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease
Herrup, K., Carrillo, M. C., Schenk, D., Cacace, A. M., DeSanti, S., Fremeau, R. T., Bhat, R. V., Glicksman, M. A., May, P. C., Swerdlow, R. H., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.017 · Cited by 54 · see citing works
Self-citationTasseff, T. L., & Nies, M. A. (2017) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000526728.75657.9e · Cited by 50 · see citing works
Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview
Morris, J. C., & Selkoe, D. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.005 · Cited by 37 · see citing works
Development of a unified clinical trial database for Alzheimer's disease
Neville, J., Kopko, S., Broadbent, S., Avilés, E., Stafford, R., Solinsky, C. M., Bain, L. J., Cisneroz, M., Romero, K., Stephenson, D. T., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.11.005 · Cited by 37 · see citing works
Self-citationPerspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease
Teipel, S. J., Sabri, O., Grothe, M. J., Barthel, H., Prvulovic, D., Büerger, K., Bokde, A. L. W., Ewers, M., Hoffmann, W. U., & Hampel, H. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129030 · Cited by 26 · see citing works
Alzheimer's disease public‐private partnerships: A landscape of the global nonprofit community
Snyder, H. M., Bain, L. J., Egge, R., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.05.1761 · Cited by 12 · see citing works
Self-citationStephenson, D. T., Avilés, E., Bain, L. J., Brumfield, M. A., Carrillo, M. C., Comery, T. A., Compton, C. C., Corrigan, B., Gordon, M. F., Jack, C. R., et al. (2013) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479013498386 · Cited by 8 · see citing works
Self-citationWorley, S. L. (2014) · PubMed · Cited by 5 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · see citing works
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125 · see citing works
Self-citationBateman, R. J., Benzinger, T. L., Berry, S., Clifford, D. B., Duggan, C., Fagan, A. M., Fanning, K., Farlow, M. R., Hassenstab, J., McDade, E. M., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.07.005 · Cited by 303 · see citing works
Self-citationAndrieu, S., Coley, N., Lovestone, S., Aisen, P. S., & Vellas, B. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00153-2 · Cited by 293 · see citing works
Conrado, D. J., Duvvuri, S., Geerts, H., Burton, J., Biesdorf, C., Ahamadi, M., Macha, S., Hather, G., Francisco Morales, J., Podichetty, J., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1782 · Cited by 21 · see citing works
Self-citation
- Authors
- Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., McKew, J., Temple, R., Fields, F. O., Salloway, S., & Katz, R.
- Affiliations
- Critical Path Institute (US)
- Alliance for Aging Research (US)
- Berry Consultants, LLC (United States) (US)
- Janssen (Belgium) (BE)
- Brigham and Women's Hospital (US)
- Oregon Health & Science University (US)
- Eisai (Japan) (JP)
- National Institutes of Health (US)
- United States Food and Drug Administration (US)
- Pfizer (United States) (US)
- Butler Hospital (US)
- Corresponding author
- Stephenson, Diane
- ORCID
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2014-12-26
- Volume
- 15
- Issue
- 1
- Pages
- 107-113
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2140132003
- Cited by
- 37
- References
- 28
- Citations by year
- 2024: 1 · 2023: 6 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 5 · 2017: 3 · 2016: 6 · 2015: 5
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Neurotherapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P30CA016672)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, adaptive trial design, biomarkers, clinical trial design, regulatory framework, university-industry collaboration, pathogenic pathways
- MeSH terms
- Academies and Institutes, Alzheimer Disease, Animals, Drug and Narcotic Control, Drug Evaluation, Humans, Antipsychotic Agents, Public-Private Sector Partnerships
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
